Traditional remedies offer opportunities, challenges

The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was developed from a plant long used to treat fevers. But researchers note that there are some extraordinary challenges. Natural remedies often rely on a volatile mix of natural ingredients that can have a radically varied effect on different people.

"Traditional medicines can be very dangerous," says Paul Herrling, Novartis' chief of corporate research. "Practitioners had no concept of statistics or of long-term consequences such as treatments that may cause cancer when used over many years."

Novartis and Merck were the only two big pharma companies to stay in the field. And a slate of biotechs joined them, including Nicholas Piramal and Phytopharm. MerLion in Singapore has been active as well after acquiring some of GlaxoSmithKline's traditional assets.

- read the article in the Financial Times

Related Articles:
Studies ponder powers of a plant derivative
A simple method for synthesizing natural compounds
Scripps team finds path to synthesizing natural compounds

Suggested Articles

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.

The treatment staved off cancer for a median of 16.4 months and shrank tumors in 61% of patients with HER2-positive breast cancer.